🔗 Share this article

As the United States continues making historic changes to its vaccine recommendations, one figure has emerged in a surprising turn: Tracy Beth Høeg, an American of Danish descent physician and public health researcher who first made her name by expressing skepticism about COVID-19 vaccines in the pandemic and has concentrated on alleged fatalities after COVID-19 immunization in her brief time at the US Food and Drug Administration (FDA).

Proposed Changes to Childhood Immunization Program

Health officials had intended to reveal major revisions to the childhood vaccine schedule in December, aligning the US with the Danish immunization schedule, according to reports – a substantial departure that would place the US out of alignment with a large portion of the world with insufficient data for public health gain. The planned update has been delayed until the next year.

Rather than the director of the vaccine center, Tracy Beth Høeg is listed to present at the event. She was recently named acting director of the FDA’s drug evaluation center, the fifth appointee to run the division this year.

A New Direction at the Agency

The acting appointment may indicate a closer partnership between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad strengthen their influence at the agency – and it points to a greater focus upon dismantling previously authorized immunizations at the FDA.

The new acting director has often pushed for halting certain childhood shot schedules in the US so as to align more like the Danish model, a society with comprehensive healthcare and a population about the population of Wisconsin’s.

So far public appearances, she has kept her attention on vaccines – typically the responsibility of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Doubts Over Background

Dr. Høeg has little discernible background in drug development, oversight or management, which has been standard for past directors of the biologics center. She has served at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have the necessary background” for leading the CDER, said Dr. Jonathan Howard. “She’s never run a scientific study. She has no expertise in running a major agency. She lacks background in pharmaceutical oversight.”

Former directors of CBER would “understand regulatory frameworks and the research of medication creation”, said a former acting FDA commissioner. “Objectively, she has not acquired the kind of background that previous people who led the center have had.”

CDER has an enormous workload at the agency, Woodcock pointed out.

“Everybody just focuses on the innovative therapies, but the generic drug division authorizes numerous generic medications. There is also a biosimilars program, OTC medication office and other areas, and each of these need to be managed,” Dr. Woodcock noted. “The area you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a major administrative component to the job, which manages more than 5,000 employees. “It is a huge management job, if you do it right,” the former official concluded.

Response and Disputed Initiatives

In response to concerns about Dr. Høeg's credentials and whether this selection signifies greater collaboration among regulatory chiefs on immunizations, a press secretary stated that the “questions are based on incorrect premises”.

“Her resume is consistent with the responsibilities of her job,” the official said, noting the period Dr. Høeg spent advising the agency head on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Dr. Høeg inherits the commissioner’s recently launched priority voucher program, a contentious expedited drug-approval program that reportedly concerned her predecessors. “How are these drugs being chosen for this expedited pathway? Who is making the calls?” Howard said. “There is a lot of confidentiality occurring at the FDA right now.”

Overall, he said, “the agency appears to be shifting towards less stringent regulations of all drugs, with the exception of vaccines.”

Established Track Record on Vaccines

With immunizations, Høeg has a more established, if problematic, track record, Howard have noted. She published a analysis using unconfirmed volunteer-provided data to determine the incidence of heart inflammation after COVID-19 immunization. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have modified findings to indicate Covid vaccinations are riskier than they are.

Part of her “policy goals” for the current federal leadership encompassed changing rules for novel immunizations and ending “optional” immunizations, she remarked after the election on a podcast. At the FDA, Dr. Høeg has allegedly suggested excluding teenage boys from obtaining COVID-19 vaccinations.

“She is an complete ideologue who begins with her conclusions and tailors the evidence to accommodate the evidence in a extremely disingenuous, fraudulent way,” Howard said.

Taking Control and a “Push for Payback”

Høeg became part of fellow dissenters, {like|